Study of BHV-4157 in Alzheimer's Disease (T2 Protect AD)
Diseases of the Nervous System | Alzheimer's Disease
What is the purpose of this trial?
Preclinical models suggest that riluzole, the active metabolite of BHV-4157, may protect from AD-related pathology and cognitive dysfunction. Titrated dose of BHV-4157 to 280 mg, or placebo, taken orally once daily. Duration of treatment is 48 weeks. There is also a screening period of up to 42 days; and a 4-week post-treatment observation period.
Alzheimer’s disease research Center http://www.alzheimers.yale.edu
- Ages50 years - 85 years
- Trial withUniversity of California, San Diego
- Start Date01/06/2019
- End Date01/01/2020
- Last Updated02/04/2019
- Study HIC#2000024024